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Purpose: To assess primary success and safety of percutaneous transluminal angioplasty (PTA) and/or stenting of
ostial/proximal common carotid artery lesions (pCCA) and to compare its 30-day stroke/mortality level with the
literature data for surgical options.
Methods:A total of 147 patients (153 stenoses, 6 recurrent) (71 female; 121 left) with significant diameter stenosis (>70%
in symptomatic, n  46; >85% in asymptomatic, n  101 patients) of pCCA treated between 1994 and 2006 were
retrospectively reviewed. With the exception of one, all procedures were performed using a transfemoral approach. A stent
was implanted in 108 (70.5%) of cases. Stents were not available in the early years of our experience, but gradually became
a routine practice. Embolic protection devices were used in 16 cases. Follow-up included neurological examination,
carotid duplex scan, and office/telephone interview.
Results: Primary technical success was 98.7% (151/153 stenoses). There were no deaths. Periprocedural (<48 hours)
neurological complications included 3/153 (2.0%) ipsilateral major strokes and 4/153 (2.6%) TIAs (including one
contralateral TIA). There were 8/153 (5.2%) access site hematomas, 1/153 (0.7%) bradycardia, and 1/153 (0.7%) acute
left ventricular failure with respiratory distress. Follow-up was achieved in 115/147 patients (78.2%) undergoing 120
procedures for a mean of 24.7 months and revealed one additional contralateral TIA and one additional minor stroke in
an asymptomatic patient. In patients with follow-up, the 30-day procedural death/all-stroke rate was 3/120 (2.5%) The
cumulative primary patency rate in the 115 patients with follow-up was 97.9% 2.1% at 1 year, 82.0% 7.1% at 4-years,
and 73.5%  12.7% at 7 years. The cumulative secondary patency rate was 100% at 1 year, 88.0%  7.0% at 4 years, and
88.0%  11% at 7 years. Log-rank test showed no statistical difference (P  .82) in primary cumulative patency between
PTA alone (n  34) or PTA/stent (n  86).
Conclusion:Transfemoral PTA/stenting appears to be appropriate treatment option for ostial/proximal common carotid
artery significant stenoses. This study should also draw attention to the lack of data on natural history or effect of best
medical treatment alone for these lesions, making evidence-based decision currently impossible for treatment of
symptomatic or asymptomatic ostial and proximal common carotid artery significant stenoses. ( J Vasc Surg 2008;48:
80-7.)Angioplasty of the supra-aortic arteries began in the
1980s. Initially, there was a fear of possible cerebral emboli-
zation,1-3 which later prompted the introduction of cerebral
protection devices. Subsequently, the endovascular treat-
ment of significant (70% luminal diameter stenoses) at
the carotid bifurcation and proximal internal carotid artery
in preventing stroke has been increasingly accepted.4-7 In
contrast, despite the region of the original proximal com-
mon carotid artery (CCA) being the second most common
location for stenosis in the extra cranial carotid territory (1%
to 2% of all carotid artery cerebral ischemia),8 there are only
a few reports involving small series of patients concerning
the success rates and safety of angioplasty and or stenting of
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80the origin of the proximal common carotid artery (pCCA).
Thus, the effectiveness of this treatment in preventing
stroke and guidelines for pCCA endovascular treatment are
yet to be determined. The purpose of our study was to
assess the primary success and safety of pCCA intervention
in a single-center, retrospective study on 153 lesions in 147
patients over the past 13 years.
MATERIALS AND METHODS
Patients. Between January 1, 1994 andDecember 31,
2006, 153 percutaneous transluminal angioplasties (PTA)
(including six repeat PTA [rePTA]/stenting procedures
done in the follow-up period) were performed on 147
consecutive patients with significant proximal common
carotid artery (pCCA) stenosis. Eighty-four percent of the
lesions were ostial stenoses, 14% proximal stenoses, and 2%
combined. Proximal CCA stenosis was diagnosed by cath-
eter angiography following an initial duplex screening.
Inclusion criteria for endovascular treatment were 70%
luminal diameter stenosis in patients with ipsilateral isch-
emic neurologic symptoms or ’85% stenosis in asymptom-
atic patients. Contraindications included suspected vessel
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decision for treatment was made by consensus between the
interventional radiologist, the vascular surgeon, and/or the
neurologist. Informed consent of patients was obtained
before the procedure in all patients.
The average diameter stenosis was 81.5%. Patient age
ranged from 21 to 83 years (mean 60.6 years). The group
included 76men and 71women. Themajority of patients had
atherosclerotic lesions, 10 patients had stenoses due to irradi-
ation, and one hadTakayasu arteritis. Therewere 104 patients
who were hypertensive, 30 with diabetes, 59 with hyperlipid-
emia, and 34 smokers. Lower limb arterial stenoses were
found in 40 patients, while 35 patients had coronary athero-
sclerosis. There were 32 common carotid artery interventions
performed on the right and 121 on the left.
Forty-six patients were symptomatic and 101 patients
were asymptomatic, including 57 patients with contralat-
eral carotid or vertebrobasilar symptoms and 44 patients
with no neurological symptoms. Presenting symptoms in
the symptomatic group were amaurosis fugax on the ipsi-
lateral side (n  9), hemispheric symptoms (n  27), and
aphasia in (n  10) patients. In the asymptomatic group,
contralateral amaurosis fugax (n  6), dysarthria (n  2),
contralateral lateralizing symptoms (n  25), subclavian
steal (n  9), drop attack (n  2), and aphasia from the
contralateral side (n  13) occurred. Greater than 50%
stenoses and/or occlusions in other supra-aortic arteries
were diagnosed in 124/153 (81,0%) of the cases. We
additionally treated 3 innominate artery stenoses, 13 ipsi-
lateral internal carotid artery stenoses, 1 contralateral exter-
nal carotid artery stenosis, and 3 contralateral subclavian
artery stenoses in one stage together with pCCA PTA.
Procedure. Before the intervention, anticoagulation
and platelet aggregation inhibition was achieved by 70 U
per kg heparin i.a., and 125 mg/d aspirin p.o. Sodium
pentosan polysulphate (100 mg), which has both anticoag-
ulative and mild fibrinolytic as well as endothelium protec-
tive effects, was also used at our institution until 2004.1-3
Angioplasty was carried out via femoral artery puncture
in all but one case. In this case, femoral puncture was not
possible due to occlusion of the femoral artery on both
sides (Leriche syndrome), and therefore, the site of entry
was the axillary artery. Over the 13 years, details of the
technique have changed with the availability of new de-
vices. Additionally, some of the variations in technical
details were lesion and operator dependent. Typically, a
polytetrafluoroethylene (PTFE) coated guidewire was used
to introduce a pigtail catheter (Cordis Corp, Miami, Fla) to
perform arch aortography. A 7F introducer guide (typically
MPA 1, Cordis Corp) was then advanced to the aortic arch.
The pCCA lesion was negotiated using a selective cerebral
catheter (Headhunter or JB2, Cordis Corp, Miami, Fla)
and a 0.035 inch guidewire (Terumo angled, Terumo
Corp, Tokyo, Japan). The size of the angioplasty balloons
were chosen based on the diameter of the CCA beyond the
lesion (7-9mm), with a length appropriate to the lesion (20
or 40 mm) (Wanda, Boston Scientific, Galway, Ireland).
The balloon was inflated for approximately 10 to 20 sec-onds until satisfactory dilatation with abolition of the
“waisting” of the balloon was achieved (6-10 atm). In case
of technical difficulties in traversing the curved stenotic
origin of the CCA, occasionally a 0.014 inch guidewire was
used to traverse the stenosis and predilatation with a per-
cutaneous transluminar angioplasty (PTCA) balloon (4.0
 20 mm, Maverick, Cordis) was performed, after which
the larger balloon catheter or stent introduction device was
easily advanced through the stenosis. Finally, completion
angiography of the treated lesion and the intracranial cir-
culation of the treated carotid artery in two projections
were performed.
A stent was implanted in 108 cases: Palmaz/Genesis
(Cordis) 61, Smart (Cordis) 4, AVE Bridge (Medtronic,
Minneapolis, Minn) 6, Wallstent (Boston Scientific, Natick,
Mass) 15, Cordis Precise Nitinol (Cordis) 11, Corinthian
(Cordis) 1, Nexstent (Boston Scientific) 1, Radix (Bio-
medica Sorin Vienna, Austria) 1, Smart Nitinol (Cordis) 1,
Wavemax (Abbott Medical, Abbott Park, Ill) 2, Xact (Ab-
bott Medical) 1, while in 4 cases from the early years no
data referring to the stent type was found. Table I shows the
number of stents used and the number of total interven-
tions annually. An embolic protection device was used in 16
cases (filter wire EZ 190 cm, Boston Scientific): 13 in the
left carotid artery (3 ostial and 10 proximal stenoses), and 3
in the right carotid (3 proximal stenoses). In 13 cases,
neuroprotection was used because of simultaneous internal
carotid artery stenting. Until 2002, protection devices were
not available at our institution.
Patients were continued on acetylsalicylic acid (100 mg
daily per p.o.) indefinitely after the PTA, provided that
there was no contraindication. Thirty-six patients were on
dual antiplatelet therapy (three patients on acetylsalicylic
acid  clopidogrel [75 mg per os] and four patients on
acetylsalicylic acid  ticlopidine per os [250 mg b.i.d.]).
Patients were usually discharged 1 day after the PTA and
were asked to come back for a follow-up examination at 1,
3, 6, 12 months, and every 6 months thereafter. Patients
were advised to come back immediately in case of observing
Table I. Number of stents and total interventions
annuallynew symptoms. Patients were strongly advised not to
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pressure tested regularly by their family physician or by us.
Follow-up. One hundred fifteen out of 147 patients
(78.2%) (undergoing 120/153 [78.4%] successful proce-
dures) had follow-up visits that included carotid duplex
scanning and a neurological examination. Clinical follow-up
was performed up to 7 years, and mean follow-up time was
24.7 months. Follow-up was carried out by an independent
neurologist and results obtained through reviewing the
medical records and clinical notes of the patients. New
relevant neurological symptoms, such as occurrence of
stroke or death were assessed as complications of the
procedure.
Definitions. Transient ischemic attack (TIA) was de-
fined as a temporary focal cerebral or retinal deficit that
resolved within 24 hours, while stroke was defined as a new
neurological deficit that persisted for a period of more than
24 hours. Technical success was defined as less than 30%
residual diameter stenosis on the completion angiogram. A
two- or threefold increase in value of peak systolic velocity
by carotid duplex examination referred to a 50% or 70%
diameter stenosis, respectively. Since direct visualization by
carotid duplex during follow-up was not always possible,
we refer to the patency rate rather restenosis-free patency
Fig 1. A and B, Successful PTA of the right proximal c
patient. Patient had follow-up duplex scan following prev
90% stenosis (PSV 450 cm/s) on the proximal part o
throughout the follow-up period. The last follow-up dup
of restenosis.rate in our analysis.Statistical analysis. The Kaplan-Meier method was
employed to calculate cumulative primary and secondary
patency rates (SPSS, Chicago, Ill), and the log rank test was
used to compare cumulative patency rates between PTA
and PTA/stent groups. The occurrence of TIA, any stroke,
or death was monitored during in-hospital stay (24 to 48
hours) (periprocedural), at 30 days (perioperative), and
through the time to the most recent follow-up. This study
had Institutional Review Board approval.
RESULTS
Primary success. The initial technical success rate was
98.7% (151 of 153 lesions in 147 patients). In two cases,
the angioplasty was not successful: in one case it was
impossible to pass the lesion with the guidewire, while in
the second occasion, the procedure was stopped before the
dilatation was done because of ipsilateral TIA (the patient
did not undergo a second attempt at endovascular therapy).
Examples of successful common carotid artery PTA are
shown on Figs 1 and 2.
Complications. There were no procedure related
deaths. Eight neurological complications (5.2%) occurred
during the in-hospital stay: 3/153 (2%) ipsilateral major
strokes during the procedure, 3/153 (2.0%) ipsilateral,
on carotid artery of a 51-year-old female, asymptomatic
internal carotid endarterectomy. Duplex scan diagnosed
t CCA. The patient remained neurologically negative
an at 17 months showed patent CCA with no indicationomm
ious
f righ
lex sc1/153 (0.7%) contralateral TIAs within 4 hours of the
no re
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(5.2%) access site bleedings (four of them required surgical
treatment), 1/153(0.7%) acute left ventricular failure with
respiratory distress, and 1/153 (0.7%) bradycardia were
also noted. The periprocedural death/all-stroke rate was
2.0% (3/153). The 30-day death/all-stroke rate was 2.5%
(3/120; see follow-up). The first patient who suffered a
major stroke developed right sided hemiplegia and dysar-
thria after stent implantation (Smartstent, Cordis) in the
left proximal common carotid artery. We observed only
mild recovery of that neurological status. The patient had
symptoms (TIA) before the intervention. Carotid duplex
scan 18 months after the procedure showed the common
carotid artery to be patent without significant stenosis.
Seventy-onemonths after the stent implantation, the symp-
toms were resolved. The second patient who suffered a
major stroke had previously had right upper limb hemipa-
resis and aphasia. Angiography revealed left common ca-
rotid and left internal carotid artery occlusion and an 80%
stenosis at the origin of the right common carotid artery;
the right external carotid artery was also occluded. Both
vertebral arteries had significant stenosis at their origin.
PTA/stent implantation (Wallstent, Boston Scientific) of
Fig 2. Successful PTA and stent (8  18 mm Genesis,
of common carotid of a 76-year-old asymptomatic female
months follow-up. A, Angiography revealed 80% stenos
stent implantation. Follow-up duplex screening showedthe right CCA and left vertebral artery was done. Duringthe procedure, the right sided hemiparesis and aphasia
deteriorated significantly. Within a week, aphasia improved,
while the right upper limb hemiparesis remained un-
changed. Thirty-five days later, the patient died due to
cardiac insufficiency and pneumonia. The third patient
developed hemiparesis on the left side after angioplasty
without stent implantation and later we lost contact with
her due to the patient’s low level of compliance.
Clinical follow-up. One hundred fifteen out of 147
(78.2%) patients, representing 120/153 (78.4%) successful
procedures were available for follow-up evaluation. Eleven
unrelated deaths (gastrointestinal and hepatic malignity)
occurred 35 days to 52 months following the procedure.
Carotid ultrasound. More than 50% diameter reste-
nosis was detected in 11/115(9.6%) patients: 51% to 69%
diameter restenoses n  2; 70% to 99% stenoses n  6;
occlusion n  3. Eight patients (7.0%) had angiography
due to different indications (see below).
Selective carotid and arch angiography. Angiography
revealed one 50% to 69% stenosis, and there was no indica-
tion for rePTA in this patient. Seventy percent to 99%
restenosis was detected in seven patients (in one patient,
CDS underestimated the degree of stenosis). Successful
is Corp, Miami, Fla) deployment in the left ostial lesion
nt. Follow-up duplex scan showed no restenosis after 18
he origin of the left CCA. B, Control angiography after
stenosis at 18 months.Cord
patie
is at trePTAwas done in six cases; one patient refused the offered
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nosis in 3 cases at 14, 16, and 18 months following rePTA.
Two of these were 50% to 69% secondary restenosis with no
indication for further intervention. One patient was offered
endovascular therapy; this patient did not consent to the
procedure by the end of the follow-up period.
Neurological examination. Two asymptomatic pa-
tients showed new neurological symptoms: one contralat-
eral TIA (19 months postprocedure) and one minor stroke
(52 months postprocedure). The cumulative primary pa-
tency rate was 97.9%  2.1% at 1 year, 82.0%  7.1% at 4
years, and 73.5%  12.7% at 84 months. The cumulative
secondary patency rate was 100% at 1 year, 88.0% 7.0% at
4 years, and 88.0%  7.0% at 84 months (Fig 3, A). The
mean primary and secondary patency times were 23.9 and
24.9 months, respectively. In the PTA-only group, the
Fig 3. A, Kaplan-Meier analysis of cumulative patency
excluding initial failures. Since the direct visualization of the
scan was not always possible during follow-up, we refer to
analysis.B,Kaplan-Meier curves of primary cumulative pate
86 proximal common carotid artery stent implantation. Lo
between PTA and PTA/stent groups. (P  .825). C, K
angioplasty and stent implantation. Log rank test was used t
PTA/stent groups (P .680).primary patency rate was 97.2%  3.6% at 1 year, 86.5% 11% at 4 years, and 79.1%  11% at 84 months. In the
PTA  stent group, the primary patency rate was 96.0% 
2.5% at 1 year and 88.2%  5.3% at 4 years and 58.1% 
12% at 74 months In the PTA  stent group, longest
follow-up was 74 months (Fig 3, B). Log-rank test showed
no statistical difference in primary (P .825) (Fig 3, B) and
in secondary (P  .680) (Fig 3, C) cumulative freedom
from restenosis between PTA alone (n 34) or PTA/stent
(n  84).
DISCUSSION
Before the era of endovascular therapy, surgical treat-
ment was the only option in the management of occlusive
disease of pCCA. Surgical revascularization of pCCA and
other supra-aortic trunk lesions is an effective and durable
treatment; however, the mortality/morbidity rate associ-
for 120 proximal common carotid artery interventions,
imal part of the common carotid arteries by carotid duplex
ncy rate” rather than “restenosis-free patency rate” in our
ate for 34 proximal common carotid artery angioplasty and
test was used to compare primary cumulative patency rate
-Meier curves of secondary cumulative patency rate for
pare secondary cumulative patency rate between PTA andrate
prox
“pate
ncy r
g rank
aplan
o comated with the transthoracic approach can be as high as 16%
osp
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duced the mortality rate of surgical repair of pCCA to 4.3%
(Table II).10 Nevertheless, having introduced the balloon
dilation method at our department in the early eighties, the
operative reconstructions of CCA was minimized to the
cases of CCA occlusions or multiple lesions of the supra-
aortic vessels. In addition, surgery is indicated in the case of
unsuccessful endovascular therapy.
Data on endovascular treatment of pCCA lesions are
scarce. There is only one other study on transfemoral
elective stenting of 42 proximal common carotid artery
lesions (Table III).11 In that study, the periprocedural
neurological complications rate was 4.7% (two minor
strokes) with an additional death due to retroperitoneal
hemorrhage within 24 hours of the procedure, leading to a
7.1% 30-day all stroke/death rate. However, the authors
Table II. Surgical revascuarization of supraaortic trunk le
Author Year
No. of
patients; cases
Trial
type
Primary
success rate
Berguer et al10 1999 173;182 Retrosp 100%
Berguer et al9 1998 98;100 Retrosp 100%
Table III. Endovascular treatment of pCCA lesions
Author Year
No. of
patients;
cases
Tri
typ
Percutaneous PTA/stent
Chio et al11 2003 37;42 Pros
Current study 2007 147;153 Retr
Surgical and retrograde PTA/stent
Peterson et al13 2006 9;9 Retr
Payne et al14 2006 8;8 Retr
Allie et al15 2004 23;23 Pros
Grego et al16 2003 10;10 Retr
Macierewicz et al17 2000 6;6 Retr
Arko et al18 2000 8;8 Retr
Levien et al19 1998 20;20 Retr
Sullivan et al20 1998 11;11 Pros
Queral et al21 1996 6;6 Pros
Motarjeme22 1996 8;8 Retrclaimed that all 30-day procedure-related neurologicalevents and deaths occurred in the first 2 years of the 5-year
period studied, and expected further reductions in peripro-
cedural events with experience and improved techniques,
such as use of protection devices.11 The neurological com-
plication rate in the current study was lower (3/115, 2.6%);
however, our study is retrospective, and follow-up was not
available for all patients due to the long time-span (13
years) of treatment.
An alternative option for treatment of pCCA lesions is
synchronous carotid endarterectomy and retrograde endo-
vascular treatment of the common carotid artery stenosis
(combined treatment) (Table III). There are numerous
reports concerning this approach (n 10), but all concern
small patient cohorts (range 6-23), therefore, any conclu-
sion from these studies are limited.
Carotid bifurcation stenting is routinely done under
Indication
5% stenosis; 82% of patients symptomatic: cerebrovascular
schemia (66%), hand ischemia (13%), LIMA steal that lead to
ngina or congestive heart failure after LIMA CABG (3%)
symptomatic: cerebrovascular ischemia in 83%; upper extremity
schemia 4%
PTA only/
PTA  stent
Primary
success rate Indication
0/42 95,00% 50% stenosis
45/108 98,60% 31.2% of patients symptomatic;
68.7% asymptomatic
0/9 100,00% 80% of patients symptomatic
(90% sten)
8/0 100,00% Severe inflow disease
0/23 97,00% Various
0/10 87,50% 12.5% TIA; 37.5% non focal
cerebral symptoms
0/6 100,00% 67% asymptomatic; 33%
cerebral ischemia
0/8 100,00% 62.5% TIA; 7.8% non disabling
stroke; 7.8% amaurosis
0/20 97,00% 43% TIA; 20.5% amaurosis;
6.8% retinal emboli; 29.7%
asymptom
0/11 92,90% 42.8% TIA; 57.1%
asymptomatic
0/6 92.3% 16.6% amaurosis; 83.3% TIAs
8/0 93% usions
7
i
a
87%
ial
e
p
osp
osp
osp
p
osp
osp
osp
osp
p
pdual antiplatelet therapy. In contrast, dual antiplatelet ther-
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of pCCA endovascular procedures, including this report.
However, use of dual antiplatelet therapy and protection
devices, when technically possible, may further reduce the
number of neurological complications associated with
pCCA endovascular treatment.
The principal advantage of stent placement in the treat-
ment of carotid artery stenoses is its impact on immediate
outcome. The stent serves to limit embolization of athero-
sclerotic debris liberated during the PTA procedure. In
addition, it reduces elastic recoil and prevents propagation
of intimal dissections created during the procedure. How-
ever, there is no evidence that stenting is superior to angio-
plasty alone for proximal CCA lesions; current practice,
however, includes primary stenting in most cases for the
reasons discussed above (Table I).
Restenosis, although an issue in essentially all vascular
Table II. Continued.
Postprocedural
antiplatelet therapy Non neurol compl p
unknown Asymptomatic graft occl.: 2%; AMI: 3%;
Pulm compl: 5%; graft infection: 1%
D
single 2 asymptomatic graft occlusions, 3
nonfatal MI, 7 significant pulmonary
complications, 3 sternal wound
infections, 1 recurrent laryngeal nerve
injury
D
Table III. Continued.
Postprocedural
antiplatelet therapy Non neurol compl
Neurol compl
periprocedural
(No. of cases)
u 2.7% retroperitoneal
hemorrhage
2 minor strokes
Double 5.2% 3 major strokes;
4 TIAs
Double 0,00% 0
Aspirin only 0,00% 0
u 0,00% 0
Aspirin only 0,00% 0
Aspirin only 0,00% 0
Double 25% wound
hematomas
1 hypoglossal
palsy
Aspirin only 4.5% hematoma 0
Aspirin only 3.4% hematoma; 1.1%
AV fistula; 1.1%
pseudoaneurysm
1 major stroke
Aspirin only 0 0
Aspirin only 0 1 major strokeinterventions, has not been a major problem in lesionsinvolving the carotid bifurcation or the adjacent internal
carotid artery. In a recent review, a 5.5% incidence of
restenosis at 12 months and 3% of repeat angioplasty for
restenosis with a mean follow-up time of 26 months was
described.12 Our restenosis and rePTA rates for the pCCA
are in a similar range. Additionally, stent placement has not
changed the restenosis rate significantly in our study (Fig 3,
B and C).
A main limitation of this study is its retrospective na-
ture. In addition, due to the long period studied (1994-
2006), the population was not homogeneous as to whether
or not stents, protection devices, and/or dual antiplatelet
therapy were used. For the same reason, follow-up is miss-
ing for 22% of the patients; however, procedural and in-
hospital clinical outcomes were available for all 153 treat-
ments. The number of restenoses, especially those below
70%, may also be underestimated due to the limitations of
ol compl
ocedural
30 days all
stroke/death
Restenosis
rate
Follow-up
month
: 0,5%;
ke: 3,8%
4,30% Primary: 5 years:
9%, 10 years: 18%
mean 535
months
: 8%,
ke: 8%
16% Primary: 5 years:
6%, 10 years: 12%
mean 514,8
months
30 days all
stroke/death Restenosis Follow-up month
/42 (7.1%) Primary 24 months: 5.1% mean 24
104 (2.8%) Primary 12 months: 4.2%;
at 48 months: 19,7%
mean 24.9
0 Primary 12 months: 0,00% mean 12
0 Primary 24 months: 12.5% mean 24
0 Primary 12 months: 8.6% mean 34
0 0.00% U
0 Primary 18 months: 16.6% median 20
0 Primary 23 months: 0.0% mean 23.6
0 Primary 12 months: 9% U
/14 (14.2%) Primary 14,3 months:
16.0%
mean 14.3
0 Primary 48 months: 15% mean 27
1/8 (12.5%) Primary 12 months: 0% mean 60Neur
eripr
eath
Stro
eath
Stro3
3/
2duplex scan examinations in direct visualization of CCA
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free patency rate in our study between angioplasty alone
and angioplasty stenting may also be due to the relatively
small sample size and the overall excellent patency rate.
CONCLUSION
In conclusion, this is one of the two studies published
on transfemoral angioplasty of ostial and proximal common
carotid artery stenosis. The primary technical success rate is
high (98.7%) with a 2.5% 30-day all stroke/death rate.
These results should help vascular surgeons and interven-
tional radiologists to consider risk versus benefit when
deciding treatment options for ostial and proximal com-
mon carotid artery significant stenoses. This study should
also draw attention to the lack of data on natural history or
effect of best medical treatment alone for these lesions,
making evidence-based decision making currently impossi-
ble for treatment of symptomatic or asymptomatic ostial
and proximal common carotid artery significant stenoses.
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